ChiCTR2500106068 版本V1.0 版本创建时间2025/07/16 17:36:31 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500106068 

最近更新日期:

Date of Last Refreshed on:

2025-07-16 17:36:11 

注册时间:

Date of Registration:

2025-07-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

关于ipRGCs介导的非成像视觉与近视相关神经调控机制的研究

Public title:

Study on ipRGCs (intrinsically photosensitive retinal ganglion cells)-mediated Non-Imaging Forming Vision and Myopia-Related Neural Regulation Mechanisms

注册题目简写:

English Acronym:

研究课题的正式科学名称:

关于ipRGCs介导的非成像视觉与近视相关神经调控机制的研究

Scientific title:

Study on ipRGCs (intrinsically photosensitive retinal ganglion cells)-mediated Non-Imaging Forming Vision and Myopia-Related Neural Regulation Mechanisms

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张晗 

研究负责人:

杨智宽 

Applicant:

Han Zhang 

Study leader:

Zhikuan Yang 

申请注册联系人电话:

Applicant telephone:

+86 176 6504 2104

研究负责人电话:

Study leader's
telephone:

+86 133 8007 1988

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

han123490@163.com

研究负责人电子邮件:

Study leader's E-mail:

han123490@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市天心区芙蓉南路一段188号

研究负责人通讯地址:

湖南省长沙市天心区芙蓉南路一段188号

Applicant address:

No. 188, Section 1, Furong South Road, Tianxin District, Changsha City, Hunan Province

Study leader's address:

No. 188, Section 1, Furong South Road, Tianxin District, Changsha City, Hunan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

长沙爱尔眼科医院

Applicant's institution:

Changsha Aier Eye Hospital

研究负责人所在单位:

长沙爱尔眼科医院

Affiliation of the Leader:

Changsha Aier Eye Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

长爱伦审字号 (2025) KYPJ022

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

长沙爱尔眼科伦理委员会

Name of the ethic committee:

Ethics Committee of Changsha Aier Eye Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-04 00:00:00

伦理委员会联系人:

方静

Contact Name of the ethic committee:

Jing Fang

伦理委员会联系地址:

湖南省长沙市天心区芙蓉南路一段188号长沙爱尔眼科医院5楼

Contact Address of the ethic committee:

Changsha Aier Eye Hospital 5 Floor, No. 188, Section 1, Furong South Road, Tianxin District, Changsha City, Hunan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 731 8522 3462

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

长沙爱尔眼科医院

Primary sponsor:

Changsha Aier Eye Hospital

研究实施负责(组长)单位地址:

湖南省长沙市天心区芙蓉南路一段188号

Primary sponsor's address:

No. 188, Section 1, Furong South Road, Tianxin District, Changsha City, Hunan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南省

市(区县):

长沙市

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

长沙爱尔眼科医院

具体地址:

湖南省长沙市天心区芙蓉南路一段188号

Institution
hospital:

Changsha Aier Eye Hospital

Address:

No. 188, Section 1, Furong South Road, Tianxin District, Changsha City, Hunan Province

经费或物资来源:

自筹

Source(s) of funding:

self-selected subject

研究疾病:

近视  

Target disease:

myopia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

从ipRGCs相关的非成像视觉过程—瞳孔变化入手,从瞳孔反应层面,综合分析其与大脑皮质功能的关系,深入探究近视眼的发病机制和潜在防控方法,为近视眼病因研究开辟新的方向  

Objectives of Study:

Starting from the pupil changes in the ipRGCs-related non-imaging visual process, this study will comprehensively analyze the relationship between pupil response and cerebral cortical function, deeply explore the pathogenesis and potential prevention and control methods of myopia, and open up a new direction for the research on the etiology of myopia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄 8-40岁; 2.正视眼双眼等效球镜度在-0.50D ~+0.50D, 3.近视眼双眼等效球镜度-1.00D~-5.00D, 4.远视眼双眼等效球镜度+0.75D~+3.00D, 5.散光及屈光参差<1D; 6.双眼最佳矫正视力≥1.0; 7.除屈光不正外,无斜视、色觉异常等眼部疾病史; 8.无眼部外伤史、手术史; 9.无癫痫等全身疾病史; 10.能配合完成各项检查

Inclusion criteria

1. Age: 8-40 years old 2. Emmetropia: binocular spherical equivalent (SE) ranging from -0.50D to +0.50D 3. Myopia: binocular spherical equivalent (SE) ranging from -1.00D to -5.00D 4. Hyperopia: binocular spherical equivalent (SE) ranging from +0.75D to +3.00D 5. Astigmatism and anisometropia: < 1D 6. Binocular best-corrected visual acuity (BCVA): >= 1.0 7. No history of ocular diseases such as strabismus or color vision abnormalities, except for refractive errors 8. No history of ocular trauma or surgery 9. No history of systemic diseases such as epilepsy 10. Able to cooperate with all examinations

排除标准:

1.不愿配合检查者; 2.拒绝签署书面知情同意或无法坚持配合完成全部检查过程者; 3.高度近视遗传史

Exclusion criteria:

1. Those who are unwilling to cooperate with the examinations; 2. Those who refuse to sign the written informed consent or are unable to persist in cooperating to complete all examination procedures; 3. Those with a family history of high myopia.

研究实施时间:

Study execute time:

From 2025-07-15 00:00:00 To 2027-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-08-09 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

正视组

样本量:

40

Group:

emmetropia group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

近视组

样本量:

40

Group:

myopia group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

远视组

样本量:

40

Group:

hyperopia group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

近视进展控制好组

样本量:

40

Group:

good control of myopia progression

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

近视进展控制差组

样本量:

40

Group:

bad control of myopia progression

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南省 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

长沙爱尔眼科医院 

单位级别:

三级 

Institution
hospital:

Changsha Aier Eye Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

瞳孔变化

指标类型:

主要指标

Outcome:

pupil change

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

大脑及视网膜电磁信号变化

指标类型:

主要指标

Outcome:

Changes in electromagnetic signals of the brain and retina

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

none

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

学术论文发表后,会通过单位所在系统上传原始数据,可联系通讯作者邮箱获取网址查看原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the academic paper is published, the original data will be uploaded through the system of the affiliated institution. The URL for viewing the original data can be obtained by contacting the corresponding author via email.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子数据采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case record form and electronic data capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-07-16 17:36:11